mRNA technology could treat autoimmune diseases, study shows
mRNA technology could help treat autoimmune diseases such as multiple sclerosis and type 1 diabetes, researchers say.
Scientists at the Biomedical Research Institute (BIOMED) at Hasselt University and the Belgian biotech company etherna have demonstrated that mRNA technology, which gained recognition for its use in Covid-19 vaccines, also holds promise for the targeted treatment of autoimmune diseases.
In a study, published in Advanced Science, researchers showed mRNA can be used not only to activate the immune system, as is the case with vaccines against infectious diseases, but also to selectively suppress harmful immune responses.
“For my team and me, developing effective treatments for people with autoimmune diseases is the greatest driving force behind everything we do,” said Professor Bieke Broux from BIOMED at Hasselt University.
“What we have achieved together with etherna is, quite honestly, remarkable. Although further validation in patients remains essential, these findings demonstrate great potential, not only for multiple sclerosis and type 1 diabetes, but possibly for a broader range of autoimmune diseases.”
New research represents ‘therapeutic progress’ in autoimmune diseases
In autoimmune diseases, the immune system mistakenly attacks healthy body tissue. Many existing treatments suppress this immune response, but they do not always do so in a targeted manner.
The new mRNA approach advanced by researchers aims to modulate the immune system more precisely. The teams successfully reduced disease severity in preclinical models of multiple sclerosis (MS) and type 1 diabetes.
One of the study’s key findings highlighted how a simple intramuscular injection proved to be just as effective as intravenous administration. This could be important for future treatments, given intramuscular injections are much easier to administer and could significantly improve the practical applicability of future mRNA therapies.
Although further research is required to demonstrate safety and efficacy in humans, these findings represent an important step towards the development of new targeted therapies for autoimmune diseases.
“For more than a decade, we have built etherna’s mRNA-LNP platform on one simple conviction: this technology is far more versatile than vaccines alone,” said Bernard Sagaert, CEO of etherna.
“These results prove it. They show that our platform can be used not only to activate the immune system, but also to calm it and re-establish immune tolerance in models of multiple sclerosis and type 1 diabetes. This achievement was only possible through collaboration.”
